IFNA1 and systemic lupus erythematosus: ,17,18,19,20,21 While disease heterogeneity is thought to be the main determinant of the variable response to IFN-I inhibition in SLE,22 the data also imply that the IFN signature may not be the optimal biomarker for identifying patients who will benefit from anti-IFN-I therapy.